OBLN – BioTuesdays

Markets

AGP ups Obalon Therapeutics to buy; PT $6.15 from 75 cents

Alliance Global Partners upgraded Obalon Therapeutics (NASDAQ:OBLN) to “buy” and raised its price target to $6.15 from 75 cents, reflecting a new valuation of ReShape Lifesciences, Obalon’s merger partner. Shares of...

February 18, 2021

Markets

AGP cuts Obalon Therapeutics to neutral; PT to 90 cents from $6.40

Alliance Global Partners downgraded Obalon Therapeutics (NASDAQ:OBLN) to “neutral” from “buy” and slashed its price target to 90 cents from $6.40 after the company moved to explore potential financial and strategic...

March 27, 2020

Developments

Obalon hires Canaccord Genuity to explore financial and strategic alternatives

The board of Obalon Therapeutics (NASDAQ:OBLN) decided to explore potential financial and strategic alternatives intended to enhance stockholder value and has retained Canaccord Genuity as its financial advisor. The...

March 25, 2020

Developments

Obalon opens second retail treatment center to treat obesity

Obalon Therapeutics (NASDAQ:OBLN) opened its second company-managed retail center in Orange County, Calif. to treat obesity with its swallowable, gas-filled intragastric balloon system. In a statement, Bill Plovanic...

February 20, 2020

Markets

BTIG cuts Obalon Therapeutics PT to $7 from $13

BTIG lowered its price target for Obalon Therapeutics (NASDAQ:OBLN) to $7 from $13 after the company reported in-line fourth quarter results and guidance for 2018. The stock finished at $4.01 on March 5. Obalon is...

March 6, 2018

Tag - OBLN

AGP ups Obalon Therapeutics to buy; PT $6.15 from 75 cents

AGP cuts Obalon Therapeutics to neutral; PT to 90 cents from $6.40

Obalon hires Canaccord Genuity to explore financial and strategic alternatives

Obalon opens second retail treatment center to treat obesity

BTIG cuts Obalon Therapeutics PT to $7 from $13

Follow Us

General

More

Sign up for the BioTuesdays weekly newsletter